Canaccord Genuity Maintains Buy on 10x Genomics, Lowers Price Target to $50
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Kyle Mikson maintains a Buy rating on 10x Genomics (NASDAQ:TXG) but lowers the price target from $65 to $50.
April 29, 2024 | 2:44 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Canaccord Genuity maintains a Buy rating on 10x Genomics but lowers the price target from $65 to $50.
While the maintenance of a Buy rating suggests continued confidence in the company's fundamentals, the reduction in the price target could reflect adjustments in market conditions or expectations for the company's future performance. This mixed signal might lead to short-term uncertainty among investors, potentially stabilizing the stock price as the market absorbs the new target.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100